| Abstract Scope |
Pulmonary Arterial Hypertension(PAH), an incurable disease where symptoms are treated with dilator drugs that have systemic side-effects. It is therefore increasingly recognized that such limitation can be overcome using nanomedicine applications. This study evaluates one particular nanoformulation (nanoMIL-89) using in vitro, in vivo models, then testing its suitability to carry the PAH drug sildenafil. In this study, nanoMIL-89 was prepared/characterized, its safety was proven using different vascular cells (endothelial and smooth muscle cells). The cardioprotective effect of the nanoMIL-89 was proven as it enhanced the eNOS activity, lowered the ET-1, CXCL-8 and DHE levels. When tested in vivo it didn’t affect the organ development. Furthermore, once loaded with Sildenafil, it prolonged its half-life and enhanced its pharmacokinetics. These results are interesting and could pave the way for improving PAH treatment, however, further pharmacological assessment of sil@nanoMIL-89, including in PAH models, is now required and constitutes the subject of ongoing investigation. |